Specifically, TP53 mutant MDS/AML patients have a median OS < 12 months despite standard of care therapy including HMA, HMA + venetoclax, and intensive therapy, as well as very poor outcomes to allogeneic HSCT. Here, TP53 is linked to acute myeloid leukemia.